1
|
Lavergne M, Iochmann S, Bléchet C, Lerondel S, Heuze-Vourc'h N, Gaud G, Lemarie E, LePape A, Guyetant S, Reverdiau P. 805 Monitoring of Human Lung Tumour Progression Inhibited by TFPI-2 Using Imaging in Mice Orthotopic Models. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71438-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
2
|
Westeel V, Lebitasy MP, Mercier M, Girard P, Barlesi F, Blanchon F, Tredaniel J, Bonnette P, Woronoff-Lemsi MC, Breton JL, Azarian R, Falcoz PE, Friard S, Geriniere L, Laporte S, Lemarie E, Quoix E, Zalcman G, Guigay J, Morin F, Milleron B, Depierre A. [IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer]. Rev Mal Respir 2007; 24:645-52. [PMID: 17519819 DOI: 10.1016/s0761-8425(07)91135-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND The authorities advocate a minimalist attitude towards the follow-up of resected bronchial carcinoma (clinical examination and chest x-ray). A survey showed that 70% of French respiratory physicians have chosen to use the CT scanner and often endoscopy. The published data are equivocal and are often based on retrospective studies. Lung cancer is a good model for a study of post-operative surveillance. Recurrences often occur in easily observed areas, they may be detected while still asymptomatic and are sometimes potentially curable. Second primary tumours may develop at the same site. METHODS The Intergroupe Francophone de Cancerologie Thoracique (IFCT) has initiated a trial comparing simple follow-up (clinical examination, chest x-ray) with a more intensive follow-up (CT scan, fibreoptic bronchoscopy). The surveillance will take place every 6 months for 2 years and then annually until 5 years. EXPECTED RESULTS The main aim is to determine whether intensive follow-up improves patient survival. The opposite question is equally important. If an expensive and demanding follow-up does not affect the chances of cure these results will influence our practice.
Collapse
Affiliation(s)
- V Westeel
- Service de Pneumologie, CHU de Besançon, Université de Franche-Comté, Besançon Cedex, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Maillet A, Congy-Jolivet N, Hureaux J, Vecellio L, Watier H, Diot P, Courty Y, Thibault G, Gagnadoux F, Urban T, Lemarie E, Heuze-Vourc’h H. 033 Effet de l’aérosolisation du cetuximab sur la liaison à l’EGFR (Epidermal Growth Factor), son efficacité anti-tumorale in vitro et sa toxicité intrinsèque chez l’animal. Rev Mal Respir 2006. [DOI: 10.1016/s0761-8425(06)71861-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Gatineau M, Dansin E, Chomy F, Lemarie E, Nouyrigat P, Oudard S, Mouawad R, Carrasco AT, Khayat D, Rixe O. Phase II combination of gefitinib and docetaxel for advanced or metastatic non-small cell lung cancer: clinical results and biological monitoring. Target Oncol 2006. [DOI: 10.1007/s11523-006-0023-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Gagnadoux F, Le Pape A, Urban T, Hureaux J, Vecellio L, Valo I, Lerondel S, Leblond V, Diot P, Racineux J, Lemarie E. 041 Étude pré-clinique d’une administration de chimiothérapie en aerosol dans le carcinome broncho-pulmonaire. Rev Mal Respir 2005. [DOI: 10.1016/s0761-8425(05)92453-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Planque C, De Monte M, Guyetant S, Lemarie E, Courty Y. 059 Différentiel expression of the kallikrein 5 and kallikrein 7 gènes in non-small cell lung cancers subtypes. Rev Mal Respir 2005. [DOI: 10.1016/s0761-8425(05)92471-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
7
|
Kieffer A, Martinet Y, Lemarie E, Brechot J, Friard S, Ferretti G, Flahault A. P-254 Preliminary results of the impact of a french randomized feasability trial of lung cancer screening on the quality of life, risk perception and smoking status: Etude Dépiscan. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80748-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Brechot J, Blanchon T, Lemarie E, Moro-Sibilot D, Milleron B, Grenier P, Flahault A. P-241 A French pilot lung cancer screening trial randomizing multislice-spiral CT scan (MSCT) vs chest X-ray (CXR): Prevalence results. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80735-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Bennouna J, Lemarie E, Grossi F, Carballido F, Sennelart H, Leger E, Douillard J. P-453 Phase I and pharmacokinetic study of the combination ofvinflunine (VFL) and gemcitabine (GEM) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts). Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80946-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
10
|
Lemarie E, Bennouna J, Grossi F, Pinel MC, Sennellart H, Longerey B, Douillard JY. Vinflunine (VFL) in combination with gemcitabine (GEM) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Preliminary results of the phase I and pharmacokinetic study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7266] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. Lemarie
- Ctr Hospitalier Univ, Tours, France; Ctr Rene Gauducheau, Saint Herblain, France; Inst Nazionale Ricerca sul Cancro, Genova, Italy; Inst de Recherche Pierre Fabre, Boulogne-Billancourt, France
| | - J. Bennouna
- Ctr Hospitalier Univ, Tours, France; Ctr Rene Gauducheau, Saint Herblain, France; Inst Nazionale Ricerca sul Cancro, Genova, Italy; Inst de Recherche Pierre Fabre, Boulogne-Billancourt, France
| | - F. Grossi
- Ctr Hospitalier Univ, Tours, France; Ctr Rene Gauducheau, Saint Herblain, France; Inst Nazionale Ricerca sul Cancro, Genova, Italy; Inst de Recherche Pierre Fabre, Boulogne-Billancourt, France
| | - M.-C. Pinel
- Ctr Hospitalier Univ, Tours, France; Ctr Rene Gauducheau, Saint Herblain, France; Inst Nazionale Ricerca sul Cancro, Genova, Italy; Inst de Recherche Pierre Fabre, Boulogne-Billancourt, France
| | - H. Sennellart
- Ctr Hospitalier Univ, Tours, France; Ctr Rene Gauducheau, Saint Herblain, France; Inst Nazionale Ricerca sul Cancro, Genova, Italy; Inst de Recherche Pierre Fabre, Boulogne-Billancourt, France
| | - B. Longerey
- Ctr Hospitalier Univ, Tours, France; Ctr Rene Gauducheau, Saint Herblain, France; Inst Nazionale Ricerca sul Cancro, Genova, Italy; Inst de Recherche Pierre Fabre, Boulogne-Billancourt, France
| | - J.-Y. Douillard
- Ctr Hospitalier Univ, Tours, France; Ctr Rene Gauducheau, Saint Herblain, France; Inst Nazionale Ricerca sul Cancro, Genova, Italy; Inst de Recherche Pierre Fabre, Boulogne-Billancourt, France
| |
Collapse
|
11
|
Gervais R, Ducolone A, Lechevalier T, Legroumellec A, Lemarie E, Quoix E, Le Pechoux C, Bardet E, Henry-Amar M, Douillard JY. Conventional radiation (RT) with daily carboplatin (Cb) compared to RT alone after induction chemotherapy (ICT) [vinorelbine (Vr)-cisplatine (P)]: Final results of a randomized phase III trial in stage III unresectable non small cell lung (NSCLC) cancer. Study CRG/BMS/NPC/96 of the French Lung Cancer Study Group FNCLCC and IFCT. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7016] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Gervais
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - A. Ducolone
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - T. Lechevalier
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - A. Legroumellec
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - E. Lemarie
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - E. Quoix
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - C. Le Pechoux
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - E. Bardet
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - M. Henry-Amar
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| | - J.-Y. Douillard
- Ctr F Baclesse, Caen, France; Ctr hospitalier Univ Hautepierre, Strasbourg, France; Inst Gustave Roussy, Villejuif, France; Ctr Hospitalier P. Chubert, Vannes, France; Hosp Bretonneau, Tours, France; Hosp Lyautey, Strasbourg, France; Ctr Rene Gauducheau, Nantes-St Herblain, France
| |
Collapse
|
12
|
Gatineau MP, Dansin E, Chomy F, Lemarie E, Nouyrigat P, Oudard S, Mouawad R, Kalla S, Khayat D, Rixe O. Soluble epidermal growth factor receptor (EGFR) and HER-2 monitoring in a Phase II combination of gefitinib (ZD1839) and docetaxel for non-small-cell lung cancer (NSCLC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. P. Gatineau
- Hopital Salpetriere, Paris, France; Centre Oscar Lambret, Lille, France; Institut Bergonie, Bordeaux, France; Hopital Bretonneau, Tours, France; Clinique Cap d'Or, La Seyne sur mer, France; Hopital Pompidou, Paris, France; AstraZeneca, Rueil, France
| | - E. Dansin
- Hopital Salpetriere, Paris, France; Centre Oscar Lambret, Lille, France; Institut Bergonie, Bordeaux, France; Hopital Bretonneau, Tours, France; Clinique Cap d'Or, La Seyne sur mer, France; Hopital Pompidou, Paris, France; AstraZeneca, Rueil, France
| | - F. Chomy
- Hopital Salpetriere, Paris, France; Centre Oscar Lambret, Lille, France; Institut Bergonie, Bordeaux, France; Hopital Bretonneau, Tours, France; Clinique Cap d'Or, La Seyne sur mer, France; Hopital Pompidou, Paris, France; AstraZeneca, Rueil, France
| | - E. Lemarie
- Hopital Salpetriere, Paris, France; Centre Oscar Lambret, Lille, France; Institut Bergonie, Bordeaux, France; Hopital Bretonneau, Tours, France; Clinique Cap d'Or, La Seyne sur mer, France; Hopital Pompidou, Paris, France; AstraZeneca, Rueil, France
| | - P. Nouyrigat
- Hopital Salpetriere, Paris, France; Centre Oscar Lambret, Lille, France; Institut Bergonie, Bordeaux, France; Hopital Bretonneau, Tours, France; Clinique Cap d'Or, La Seyne sur mer, France; Hopital Pompidou, Paris, France; AstraZeneca, Rueil, France
| | - S. Oudard
- Hopital Salpetriere, Paris, France; Centre Oscar Lambret, Lille, France; Institut Bergonie, Bordeaux, France; Hopital Bretonneau, Tours, France; Clinique Cap d'Or, La Seyne sur mer, France; Hopital Pompidou, Paris, France; AstraZeneca, Rueil, France
| | - R. Mouawad
- Hopital Salpetriere, Paris, France; Centre Oscar Lambret, Lille, France; Institut Bergonie, Bordeaux, France; Hopital Bretonneau, Tours, France; Clinique Cap d'Or, La Seyne sur mer, France; Hopital Pompidou, Paris, France; AstraZeneca, Rueil, France
| | - S. Kalla
- Hopital Salpetriere, Paris, France; Centre Oscar Lambret, Lille, France; Institut Bergonie, Bordeaux, France; Hopital Bretonneau, Tours, France; Clinique Cap d'Or, La Seyne sur mer, France; Hopital Pompidou, Paris, France; AstraZeneca, Rueil, France
| | - D. Khayat
- Hopital Salpetriere, Paris, France; Centre Oscar Lambret, Lille, France; Institut Bergonie, Bordeaux, France; Hopital Bretonneau, Tours, France; Clinique Cap d'Or, La Seyne sur mer, France; Hopital Pompidou, Paris, France; AstraZeneca, Rueil, France
| | - O. Rixe
- Hopital Salpetriere, Paris, France; Centre Oscar Lambret, Lille, France; Institut Bergonie, Bordeaux, France; Hopital Bretonneau, Tours, France; Clinique Cap d'Or, La Seyne sur mer, France; Hopital Pompidou, Paris, France; AstraZeneca, Rueil, France
| |
Collapse
|
13
|
Quoix E, Lebeau B, Depierre A, Ducolone A, Moro-Sibilot D, Milleron B, Breton JL, Lemarie E, Pujol JL, Brechot JM, Zalcman G, Debieuvre D, Vaylet F, Vergnenegre A, Clouet P. Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy fornon-small-cell lung cancer. Ann Oncol 2004; 15:38-44. [PMID: 14679117 DOI: 10.1093/annonc/mdh005] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The survival benefit associated with first-line chemotherapy in advanced lung cancer led to the need for second-line chemotherapy. Docetaxel (Taxotere) has proven efficacy in both settings. This study evaluated the safety and efficacy of two doses of docetaxel in patients with non-small-cell lung cancer who had failed first-line platinum-based chemotherapy. PATIENTS AND METHODS In total, 182 patients from 24 French centres were randomised and treated with either docetaxel 75 mg/m(2) (arm A) or 100 mg/m(2) (arm B) every 3 weeks. Baseline characteristics were well balanced, except more patients in arm A had metastatic disease (91.4% versus 78.7%) and therefore the median number of sites involved for arm A was three compared with two for arm B. RESULTS Median time to treatment failure was 1.34 months [95% confidence interval (CI) 1.28-1.64] for arm A and 1.64 months (95% CI 1.34-2.62) for arm B. Median overall survival was 4.7 months (95% CI 3.8-5.9) for arm A versus 6.7 months (95% CI 4.8-7.1) for arm B. According to a blinded expert panel, disease control was achieved in 35 (43.8%) patients in arm A and 39 (49.4%) patients in arm B. More patients in arm B experienced grade 3-4 neutropenia (B: 72.7% versus A: 44.0%), asthenia (B: 20.2% versus A: 10.8%) and infection (B: 6.7% versus A: 2.2%). Three treatment-related deaths were reported in each arm. CONCLUSIONS The optimal docetaxel dosage in this second-line setting is 75 mg/m(2), as it has a more favourable safety profile and on balance a similar efficacy to the 100 mg/m(2) dose.
Collapse
Affiliation(s)
- E Quoix
- Hôpital Lyautey, Strasbourg, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Youssef M, Carre P, Asquier E, Janin P, Lemarie E, Diot P. [Miliary pulmonary tuberculosis following intravesical BCG-therapy]. Rev Pneumol Clin 2003; 59:201-204. [PMID: 14699296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
A patient given intravesical BCG immunotherapy developed miliary pulmonary tuberculosis. After resection of a superficial bladder tumor, the patient was given weekly intravesical BCG infusions. After the 4th session, the patient developed fever (40 degrees C), shivers, dry cough, profuse sweating, and weight loss. Initially, the chest x-ray was normal. The patient was given isoniazid (5 mg/kg) in a single-drug regimen. Rapid degradation of the general status led to a new chest x-ray, 10 days later, which demonstrated a reticulonodular syndrome. High-resolution thoracic CT confirmed the diagnosis of miliary pulmonary tuberculosis. A three-drug antituberculosis regimen associated with corticosteroids was followed by restoration of the general status. Antituberculosis therapy was continued for 9 months. The 9-month thoracic CT revealed a smaller number of micronodules in the pulmonary parenchyma. This case illustrates the discussion concerning the appropriate treatment for patients who develop a systemic infection after intravesical BCG-therapy.
Collapse
Affiliation(s)
- M Youssef
- Service de Pneumologie et d'Explorations Fonctionnelles et Respiratoires, CHU Bretonneau, 2, boulevard Tonnellé, 37044 Tours 1
| | | | | | | | | | | |
Collapse
|
15
|
Germanaud J, Proffit V, Janvoie B, Lemarie E, Lasfargues G. [Pneumopathy due to isocyanate hypersensitivity: recognition as an occupational disease]. Rev Mal Respir 2003; 20:443-9. [PMID: 12910121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
INTRODUCTION Hypersensitivity pneumopathies (HSP) are listed as number 66 in the list of occupational diseases but this list includes regulatory requirements that are not applicable to isocyanates. The authors report the case of a worker exposed to isophane di-isocyanate (IPDI) during the manufacture of polyurethane foam. CASE REPORT The diagnosis of HSP was based on the clinical presentation (dyspnoea, fever, crepitant rales) and the complimentary investigations (ground glass appearance on the thoracic CT scan, lymphocytosis in the broncho-alveolar lavage). It was confirmed by trans-bronchial biopsy. Only the functional assessment (airflow obstruction and absence of marked reduction in CO transfer) was atypical. With regard to the role of isocyanates the number of published cases (49 since the first observation in 1976) shows that this aetiology is rare. In the case presented the chronology of symptoms (regression following exclusion and immediate relapse following re-exposure) and the absence of exposure to other agents known to cause HSP confirm the aetiology with near certainty. This case was recognised within the framework of the complimentary procedure that allows for unlisted diseases. CONCLUSION In order to assist the management and recognition of HSP due to isocyanates there is good reason to raise the awareness of the medical profession and to extend the list of occupational diseases.
Collapse
Affiliation(s)
- J Germanaud
- CNAMTS service médical région Centre, Orléans.
| | | | | | | | | |
Collapse
|
16
|
Treat J, Schiller J, Quoix E, Mauer A, Edelman M, Modiano M, Bonomi P, Ramlau R, Lemarie E. ZD0473 treatment in lung cancer: an overview of the clinical trial results. Eur J Cancer 2002; 38 Suppl 8:S13-8. [PMID: 12645908 DOI: 10.1016/s0959-8049(02)80016-8] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Three open-label, non-comparative, multicentre Phase II trials have examined the efficacy and tolerability of ZD0473 as first-and second-line therapy in non-small-cell lung cancer (NSCLC) patients and second-line therapy in small-cell lung cancer (SCLC) patients. Patients with second-line NSCLC or SCLC were evaluated as either platinum-sensitive or -resistant, based upon their time to relapse/progression after platinum-based therapy. First-line NSCLC patients (n = 18) received a total of 60 treatment cycles (median number per patient 2.5) whilst second-line NSCLC (n = 50) and SCLC (n = 48) patients both received a total of 127 treatment cycles (median number per patient 2.0). Grade 3/4 anaemia, neutropenia and thrombocytopenia was observed in: 38.8%, 22.2% and 27.7% of first-line NSCLC patients; 12.0%, 24.0% and 50% of second-line NSCLC patients; and 10.4%, 25.0% and 47.9% of second-line SCLC patients, respectively. The most common grade 3/4 non-haematological toxicities in all three trials were lethargy and dyspnoea. No clinically significant oto-, nephro- or neurotoxicity was observed. The first-line treatment of NSCLC produced an overall response rate (OR) of 6.3%. No OR was seen after second-line treatment of NSCLC, while ORs of 15.4% and 8.3% were seen in the platinum-resistant and -sensitive second-line SCLC patients, respectively.
Collapse
Affiliation(s)
- J Treat
- Fox Chase Temple University Cancer Center, Philadelphia, PA, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Koninck JC, Diot E, Hazouard E, Machet MC, Valentin JF, Lemarie E, Diot P. [Bronchectasia and microscopic polyangeitis]. Rev Pneumol Clin 2002; 58:290-295. [PMID: 12486380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Microscopic polyangeitis is a necrosing vascularitis with pulmonary and renal tropism. Localized in the lung, microscopic polyangeitis leads to intra-alveolar hemorrhage. We report our observations in two patients who presented with concomitant bronchectasia. The parallel course of these two conditions suggests a possible relationship. We propose a pathophysiological approach involving a direct role of polymorphonuclear neutrophils and neutrophilic proteases secreted in response to activation of anti-polymorphonuclear cytoplasm anti-bodies (ANCA) during microscopic polyangeitis aggravating bronchectasia.
Collapse
Affiliation(s)
- J-C Koninck
- Service de Pneumologie, 2 bis, boulevard Tonnellé 37000 Tours.
| | | | | | | | | | | | | |
Collapse
|
18
|
Diot E, Lesire V, Guilmot JL, Metzger MD, Pilore R, Rogier S, Stadler M, Diot P, Lemarie E, Lasfargues G. Systemic sclerosis and occupational risk factors: a case-control study. Occup Environ Med 2002; 59:545-9. [PMID: 12151611 PMCID: PMC1740346 DOI: 10.1136/oem.59.8.545] [Citation(s) in RCA: 90] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
AIMS A case-control study was carried out between 1998 and 2000 to investigate the relation between systemic sclerosis and occupational exposure. METHODS Eighty cases of systemic sclerosis admitted consecutively to the Department of Internal Medicine at the University Hospital of Tours from 1998 to 2000 were included. For each case, two age, gender, and smoking habits matched controls hospitalised during the same period in the same department were selected. A committee of experts was set up retrospectively to assess occupational exposure. Exposure to silica dust and organic solvents (such as trichlorethylene and other chlorinated solvents, and benzene and other aromatic solvents) was investigated using semiquantitative estimates of exposure. An exposure score was calculated for each subject based on probability, intensity, daily frequency, and duration of exposure for each period of employment. The final cumulative exposure score was obtained, taking into account all periods of employment. RESULTS Significant associations with SS were observed for crystalline silica, trichlorethylene, chlorinated solvents, toluene, aromatic solvents, ketones, white spirit, epoxy resins, and welding fumes. Risk of SS was significantly associated with a high final cumulative exposure score of occupational exposure to crystalline silica, trichlorethylene, chlorinated solvents, welding fumes, and any types of solvents. CONCLUSION Results confirm the influence of occupational risk factors in the occurrence of SS in both men and women. The link is not only with silica but also with other compounds such as solvents.
Collapse
Affiliation(s)
- E Diot
- INSERM EMI-U 00-10, Groupe de Pneumologie, CHU Bretonneau, 2 bd Tonnellé, F-37044 Tours Cedex 1, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Depierre A, Freyer G, Jassem J, Orfeuvre H, Ramlau R, Lemarie E, Koralewski P, Mauriac L, Breton JL, Delozier T, Trillet-Lenoir V. Oral vinorelbine: feasibility and safety profile. Ann Oncol 2001; 12:1677-81. [PMID: 11843244 DOI: 10.1023/a:1013567022670] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Patient preference as well as concerns and difficulties with intravenous access and pharmaco-economic issues have driven the development of oral vinorelbine. PATIENTS AND METHODS Four phase II studies were conducted in chemotherapy-naive non-small-cell lung cancer (NSCLC) and as first-line chemotherapy of advanced breast cancer (ABC). As recommended in the phase I dose-finding study, the first step used a weekly dose of 80 mg/m2. This regimen was associated with an excessive rate of early deaths (10%) due to complicated neutropenia and led to discontinuation of the first two studies. In a second step, the dose of 60 mg/m2/week was given for the first three courses and subsequently increased to 80 mg/m2/week, in the absence of severe neutropenia. RESULTS One hundred and thirty eight patients (76 with NSCLC and 62 with ABC) received this regimen, of whom only five were unable to undergo dose escalation. The incidence of febrile neutropenia and neutropenic sepsis were low (2.9 and 3.6%, respectively). Although severe events were uncommon, nausea/vomiting and diarrhoea were frequent and primary prophylaxis with antiemetics should be recommended. CONCLUSIONS Overall, the safety profile of oral vinorelbine at 60 mg/m2/week for the first three courses with escalation to 80 mg/m2 is qualitatively comparable to that of i.v. vinorelbine at standard doses. Similarly to i.v. chemotherapy, close haematological monitoring is necessary.
Collapse
Affiliation(s)
- A Depierre
- Department of Pneumology, Centre Hospitalier Universitaire Minjoz, Besançon, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Attucci S, Maillot F, Degenne D, Brunereau L, Dreyfuss P, Lemarie E, Hazouard E. [Beginning rheumatoid arthritis revealed during bronchiectasis surinfections. Value of cyclic antibiotherapy?]. Rev Pneumol Clin 2001; 57:303-307. [PMID: 11593157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Incidence of symptomatic bronchiectasis (BR) occurs in around 2% in patients with late rheumatoid arthritis (RA). Its seems that the association BR-RA could be a worsening factor for outcome of RA patients. A 58-year-old woman without dry syndrome, suffering from bronchial purulence over one year was admitted to the Department of Pneumology for hemoptysis and arthritis (knees, ankles, and wrists). Three prior episodes of inflammatory articular pain had occurred after transient bronchial purulence or pneumonitis. CT-scan showed bilateral bronchiectasis. Diagnosis of early RA was proved after the third episode of bronchial purulence related to a strain of Haemophilus influenzae. A strain of Coxiella burnetii was probably responsible for one of the three bronchial surinfections. Latex and Waaler Rose tests were transiently positive during the first episode, and became positive after the third one. At that time, RA was relevant in view of ARA criteria. Cyclic prophylactic antibiotic regimens could be proposed to patients suffering from RA-BR association, in contrast to the cases of patients with isolated BR. This approach could prevent destabilization of RA and reinforce of anti-rheumatic therapy. Activation and release of cytokines (NFk-B, TNF-alpha), and/or bacterial epitopes seems to be directly responsible for the articular destabilization.
Collapse
Affiliation(s)
- S Attucci
- INSERM EMI-U 00-10, Groupe de Biochimie, Faculté de Médecine, F-37032 Tours, France
| | | | | | | | | | | | | |
Collapse
|
21
|
Touboul E, Lagrange JL, Theobald S, Astoul P, Baldeyrou P, Bardet E, Bazelly B, Bréchot J, Breton JL, Douillard JY, Grivaux M, Jacoulet P, Khalil A, Le Chevalier T, Lemarie E, Martinet Y, Massard G, Milleron B, Moro-Sibilot D, Paesmans M, Pujol JL, Quoix AE, Ranfaing E, Rivière A, Sancho-Garnier H, Souquet PJ, Spaeth D, Stoebner-Delbarre A, Thiberville L, Vaylet F, Vergnon JM, Westeel V, Depierre A. [Standards, Options and Recommendations for the management of stage I or II primary bronchial cancers treated exclusively with radiotherapy]. Cancer Radiother 2001; 5:452-63. [PMID: 11521393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
CONTEXT The 'Standards, Options and Recommendations' (SOR) project, started in 1993, is a collaboration between the Federation of the French Cancer Centres (FNCLCC), the 20 French cancer centres and specialists from French public universities, general hospitals and private clinics. The main objective is the development of clinical practice guidelines to improve the quality of health care and outcome for cancer patients. The methodology is based on literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery. OBJECTIVES To develop clinical practice guidelines according to the definitions of the Standards, Options and Recommendations project for the management of stage I and II non small cell lung carcinoma treated by radiotherapy alone. METHODS Data were identified by searching Medline and personal reference lists of members of the expert groups. Once the guidelines were defined, the document was submitted for review to independent reviewers, and to the medical committees of the 20 French cancer centres. RESULTS The main recommendations for the management of stage I and II non small cell lung carcinoma treated by radiotherapy alone are: 1) The curative external irradiation with a continual course is an alternative to surgery only in the case of medically inoperable tumors or because the patient refuses surgery; 2) The external irradiation of the primary tumor only without the mediastinum could be proposed in peripheral stage IA. In proximal stage IA and IB, external irradiation should be carried out only as part of prospective randomised controlled trials comparing a localised irradiation of the primary tumor with a large irradiation of the mediastinum and the primary tumor. The treated volume must include the macroscopic tumoral volume with or without the microscopic tumoral volume and with a security margin from 1.5 to 2 cm; 3) There is a benefit to delivering a total dose in the primary tumor higher than 60 Gy in so far as the proposed irradiation, taking into account the respiratory function, does not increase the likelihood of severe adverse events due to radiation; and 4) The change in fractionation, the radiochemotherapy combination, the endobronchial brachytherapy with high dose rate alone or with external irradiation could be proposed only as part of prospective controlled trials for tumors classified as stage IB or II.
Collapse
|
22
|
Bardet E, Moro-Sibilot D, Le Chevalier T, Massard G, Douillard JY, Theobald S, Astoul P, Baldeyrou P, Bazelly B, Bréchot J, Breton JL, Grivaux P, Jacoulet P, Khalil A, Lemarie E, Martinet Y, Milleron B, Paesmans M, Pujol JL, Quoix AE, Ranfaing E, Rivière A, Sancho-Garnier H, Souquet PJ, Spaeth D, Stcebner-Delbarre A, Thiberville L, Touboul E, Vaylet F, Vergnon JM, Westeel V, Depierre A, Lagrange JL. [Standards, options and recommendations for the management of locally advanced non small cell lung carcinoma]. Bull Cancer 2001; 88:369-87. [PMID: 11371371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
Abstract
CONTEXT The "Standards, Options and Recommendations" (SOR) project, started in 1993, is a collaboration between the Federation of the French Cancer Centres (FNCLCC), the 20 French Cancer Centres and specialists from French Public Universities, General Hospitals and Private Clinics. The main objective is the development of clinical practice guidelines to improve the quality of health care and outcome for cancer patients. The methodology is based on literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery. OBJECTIVES To develop clinical practice guidelines according to the definitions of the Standards, Options and Recommendations project for the management of locally advanced non small cell lung carcinoma. METHODS Data were identified by searching Medline and the personal reference lists of members of the expert groups. Once the guidelines were defined, the document was submitted for review to independent reviewers and to the medical committees of the 20 French Cancer Centres. RESULTS The main recommendations are: 1) The management of the locally advanced non small cell lung carcinoma has two main goals: firstly to obtain local control of the disease (or to at least delay local progression in order to improve the survival or relapse free survival), and secondly to prevent the development of metastases. 2) There is a consensus that locally advanced non small cell lung carcinoma should be irradiated. External beam radiotherapy should be of optimal quality and delivered at a minimal dose of 60 Gy by standard fractionation. For patients with a poor life expectancy, this can be delivered as a split-course or hypofractionated scheme. 3) Treatment for patients with a performance status of 0-1 should consist of short duration induction chemotherapy (with a least two drugs one of which must be cisplatin), combined sequentially with conventional radiotherapy. 4) Surgery is contraindicated in extensive N3 disease. Combined radio-chemotherapy (adjuvant or neoadjuvant) is not indicated outside clinical trials. Surgery is justified in stage N2 disease as good local control can be achieved. T4-N0 disease should be treated surgically with curative intent.
Collapse
Affiliation(s)
- E Bardet
- Standards, Options, Recommandations, 101, rue de Tolbiac, 75654 Paris Cedex 13
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Saint-Georges F, Bibi R, Roy F, Brunnereau L, Rouleau P, Diot P, Lemarie E. [An unusual thoracic opacity]. Rev Mal Respir 2000; 17:1115-6. [PMID: 11217511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
We report a case of a paraspinal meningocele in a 37-year-old man with no other clinical manifestation. The diagnosis was established on the basis of the computed tomography and magnetic resonance imaging features.
Collapse
Affiliation(s)
- F Saint-Georges
- Service de Pneumologie, CHU Bretonneau, BD Tonnellé, 37044 Tours
| | | | | | | | | | | | | |
Collapse
|
24
|
Pujol J, Daures J, Riviere A, Quoix E, Depierre A, Breton J, Lemarie E, Poudex M, Milleron B, Moro D, Debieuvre D, Quantin X, Le Chevalier T. Etoposide-cisplatin (EP) versus four-drug combination etoposide-cisplatin-epirubicin-cyclophosphamide (PCDE) in extensive disease small cell lung cancer (ED-SCLC). A FNCLCC phase III multicentre study. Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80093-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
25
|
Depierre A, Jassem J, Ramlau R, Karnicka-Mlodkowska H, Krawczyck K, Krzakowski M, Zatloukal P, Lemarie E, Hartmann W, Novakova L, O'Brien M, His Danel P, Soulas F. Feasibility and safety of Navelbine oral (NVBpo) with an intrapatient dose escalation versus Navelbine intravenous (NVBiv) in advanced/metastatic non small cell lung cancer (NSCLC). Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80112-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
26
|
Depierre A, Milleron B, Chevret S, Moro D, Braun D, Quoix E, Lebeau B, Breton J, Lemarie E, Gouva S, Paillot N, Brechot J, Janicot H, Lebas F, Terrioux P, Foucher P, Monchatre M, Coetmeur D, Clavier J, Villeneuve A, Chastang C, Westeel V. French phase III trial of preoperative chemotherapy (PCT) in resectable stage I (except T1N0), II, IIIa non-small cell lung cancer (NSCLC). Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80297-4] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
27
|
Bennouna J, Monnier A, Rivière A, Milleron B, Lemarie E, Trillet-Lenoir V, Soussan-Lazard K, Berille J, Douillard JY. A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer. Eur J Cancer 2000; 36:1107-12. [PMID: 10854943 DOI: 10.1016/s0959-8049(00)00097-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
A phase II study was conducted to determine the efficacy and the safety of docetaxel combined with vinorelbine as first-line chemotherapy in patients with metastatic or unresectable non-small cell lung cancer (NSCLC). 39 patients, median age 54 years (range: 35-69), with stage IIIB (5 patients; 13%) or IV (34 patients; 87%) NSCLC were treated with 75 mg/m(2) docetaxel given intravenously (i. v.) over 1 h on day 1 and with 20 mg/m(2) vinorelbine given i.v. over 15 to 30 min on days 1 and 5. Cycles were repeated every 3 weeks. 9 of the 39 patients had a partial response (overall response rate 23.1%, 95% confidence interval (CI): 11.1-39.3%) with a median duration of response of 20 weeks (95% CI; 17-30). The median survival was 40 weeks (95% CI: 21-49 weeks) with a 1-year survival rate of 31% in the intent-to-treat population. Neutropenia grade IV occurred in 33 patients (92%). 16 patients (41%) experienced febrile neutropenia with a concomitant stomatitis in 9 patients (23%). One patient died due to febrile neutropenia associated with a grade 4 stomatitis and 1 patient due to a septicaemia concomitant with a grade 4 neutropenia. Although the combination of docetaxel and vinorelbine is feasible, the efficacy does not seem to be improved compared with single-agent docetaxel or vinorelbine and the rate of febrile neutropenia is unacceptable in this population with incurable disease. Therefore, different doses and/or schedules are to be explored.
Collapse
Affiliation(s)
- J Bennouna
- Centre René Gauducheau, CRLCC Nantes-Atlantique, 44805, Saint Herblain Cedex, France
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Lemarie E. [Management of non-small-cell bronchial cancers. Which postoperative follow-up, which complementary examinations, at what frequency?]. Rev Mal Respir 1999; 16 Suppl 3:S128-9. [PMID: 10088284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Affiliation(s)
- E Lemarie
- Département des Maladies Respiratoires, CHU Bretonneau, Tours
| |
Collapse
|
29
|
Mairovitz A, Besnier M, Diot P, Asquier E, Dumont P, de Muret A, Lemarie E. [Bronchiolitis obliterans organizing pneumonia: a complication of radiotherapy]. Rev Pneumol Clin 1997; 53:207-209. [PMID: 9616821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Affiliation(s)
- A Mairovitz
- Service de Pneumologie, CHU Bretonneau, Tours
| | | | | | | | | | | | | |
Collapse
|
30
|
Duţu S, Bogdan M, Stoicescu P, Didilescu C, Bâscă N, Mihălţan F, Păun G, Spânu V, Ioanăş M, Jeannin L, Lemarie E, Muir F, Portier F. [The 25th National Conference of Pneumophthisiology, 17-18 October 1996, Poiana Braşov. Roundtable: care in chronic obstructive bronchopulmonary diseases]. Pneumoftiziologia 1997; 46:73-88. [PMID: 9289242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
31
|
Saint-Georges F, Diot P, Fontaine V, Dumont P, Bremont JL, Degenne M, Lemarie E. [Thymoma and dilatation of the bronchi]. Rev Pneumol Clin 1997; 53:154-156. [PMID: 9296117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Thyomas are benign or malignant lymphoepitelial tumors often associated with parathymic syndromes. A 74-year-old subject developed a recurrent thyoma over 15 year with bronchial dilatations and repeated bronchopulmonary and sinus infections. This clinical presentation suggests Good's syndrome which combines thyoma, bronchial dilatations and hypogammaglobulinemia.
Collapse
|
32
|
Goupille P, Diot P, Valat JP, Lemarie E, Valat C, Asquier E, Delarue A, Le Pape A. Imaging of pulmonary disease in rheumatoid arthritis using J001X scintigraphy: preliminary results. Eur J Nucl Med 1995; 22:1411-5. [PMID: 8586087 DOI: 10.1007/bf01791150] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The purpose of this study was to determine the ability of technetium-99m J001X scintigraphy to image active pulmonary involvement in patients suffering from rheumatoid arthritis (RA). J001X is a fully characterized acylated poly(1,3)galactoside, isolated from Klebsiella membranes, which is able to bind recruited macrophages after aerosol administration. J001X scintigraphy was compared with high-resolution computed tomography (HRCT), pulmonary function tests (PFTs) and bronchoalveolar lavage (BAL) in 15 patients suffering from RA. Patients were considered to have pulmonary involvement when they had an interstitial syndrome on HRCT and a decrease of 20% in TCO/VE (transfer coefficient) on PFTs and/or an abnormal BAL (lymphocytosis higher than 20% and/or percentage of neutrophils higher than 10%). Pulmonary involvement was present in eight patients, and absent in seven. Of the eight patients with pulmonary involvement, all had abnormal BAL, two had an interstitial syndrome on HRCT, two had decreased TCO/VE and three had positive J001X scintigraphy. Of the seven patients without pulmonary involvement, six had normal BAL (not available in one), two had an interstitial syndrome on HRCT, one had decreased TCO/VE and two had positive J001X scintigraphy. According to our gold standard of pulmonary involvement, the sensitivity of J001X scintigraphy for the detection of pulmonary involvement in RA was 37.5%, the specificity was 71.4% and the positive predictive value was 60%. The ability of J001X scintigraphy to detect active pulmonary involvement during RA appears unclear in this study but it may detect processes unnoticed by the other modalities. These patients will be followed 12 and 24 months later and the changes in J001X scintigraphy, HRCT and PFTs will be compared to demonstrate whether J001X scintigraphy is able to assess an active process in the pulmonary involvement during RA and to specify its predictive value.
Collapse
Affiliation(s)
- P Goupille
- Service de Rhumatologie, Hôpital Trousseau, Tours, France
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Diot E, Diot P, Valat C, Boissinot E, Asquier E, Lemarie E, Guilmot JL. Predictive value of serum III procollagen for diagnosis of pulmonary involvement in patients with scleroderma. Eur Respir J 1995; 8:1559-65. [PMID: 8575585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
High resolution computed tomography (HRCT) was recently demonstrated to be as good as open lung biopsy for the diagnosis of pulmonary involvement in patients with scleroderma. Nevertheless, in view of its price and related irradiation, HRCT cannot be recommended as a screening test. Serum III procollagen (sPIIINP) is an aminopropeptide of type III collagen, which is released during conversion into collagen by specific proteases. Increased levels of sPIIINP have been observed in patients with scleroderma. The aim of the present study was to assess the relationship between sPIIINP measurement and pulmonary involvement defined according to HRCT and pulmonary function tests (PFT) with single-breath carbon monoxide transfer capacity (TL,CO) in 28 patients suffering from scleroderma. Patients were divided into two groups for analysis, Group A comprising 16 patients without pulmonary scleroderma and Group B comprising 12 patients with pulmonary scleroderma. All patients had stable cutaneous disease and normal renal and hepatic function. The level of sPIIINP was determined by radioimmunoassay (RIA-gnost P-III-P, Prod. Nr. ODMT; Behring, Marburg, Germany). Mean +/- SD sPIIINP level in Group A was 0.85 +/- 0.21 U.mL-1. Individual values ranged 0.6-1.3 U.mL-1. Mean +/- SD sPIIINP value was 1.30 +/- 0.40 U.mL-1 in Group B and individual values ranged 0.7-1.9 U.mL-1. The difference in mean sPIIINP level between Group A and Group B was significant. Using a cut-off at 1.1 U.mL-1, sensitivity of sPIIINP was 0.66, specificity 0.94, positive predictive value 0.89, negative predictive value 0.79, false positive rate 0.06, and false negative rate 0.33. The value of sPIIINP correlated with HRCT score but not with PFT. This study confirms the relationship between sPIIINP and scleroderma with interstitial lung disease. We suggest that sPIIINP could be measured in patients with scleroderma to screen those patients requiring HRCT. Further studies are necessary to determine the value of sPIIINP in terms of prognosis and follow-up of patients under treatment.
Collapse
Affiliation(s)
- E Diot
- Service de Médecine Interne, CHU Bretonneau, Tours, France
| | | | | | | | | | | | | |
Collapse
|
34
|
Diot E, Diot P, Valat C, Boissinot E, Asquier E, Lemarie E, Guilmot JL. Predictive value of serum III procollagen for diagnosis of pulmonary involvement in patients with scleroderma. Eur Respir J 1995. [DOI: 10.1183/09031936.95.08091559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
High resolution computed tomography (HRCT) was recently demonstrated to be as good as open lung biopsy for the diagnosis of pulmonary involvement in patients with scleroderma. Nevertheless, in view of its price and related irradiation, HRCT cannot be recommended as a screening test. Serum III procollagen (sPIIINP) is an aminopropeptide of type III collagen, which is released during conversion into collagen by specific proteases. Increased levels of sPIIINP have been observed in patients with scleroderma. The aim of the present study was to assess the relationship between sPIIINP measurement and pulmonary involvement defined according to HRCT and pulmonary function tests (PFT) with single-breath carbon monoxide transfer capacity (TL,CO) in 28 patients suffering from scleroderma. Patients were divided into two groups for analysis, Group A comprising 16 patients without pulmonary scleroderma and Group B comprising 12 patients with pulmonary scleroderma. All patients had stable cutaneous disease and normal renal and hepatic function. The level of sPIIINP was determined by radioimmunoassay (RIA-gnost P-III-P, Prod. Nr. ODMT; Behring, Marburg, Germany). Mean +/- SD sPIIINP level in Group A was 0.85 +/- 0.21 U.mL-1. Individual values ranged 0.6-1.3 U.mL-1. Mean +/- SD sPIIINP value was 1.30 +/- 0.40 U.mL-1 in Group B and individual values ranged 0.7-1.9 U.mL-1. The difference in mean sPIIINP level between Group A and Group B was significant. Using a cut-off at 1.1 U.mL-1, sensitivity of sPIIINP was 0.66, specificity 0.94, positive predictive value 0.89, negative predictive value 0.79, false positive rate 0.06, and false negative rate 0.33. The value of sPIIINP correlated with HRCT score but not with PFT. This study confirms the relationship between sPIIINP and scleroderma with interstitial lung disease. We suggest that sPIIINP could be measured in patients with scleroderma to screen those patients requiring HRCT. Further studies are necessary to determine the value of sPIIINP in terms of prognosis and follow-up of patients under treatment.
Collapse
|
35
|
Abstract
The aim of the present study was to characterize amphotericin B aerosols nebulized by ultrasonic and jet nebulizers and to study their deposition and pharmacokinetics in patients with pulmonary mycetoma. The aerodynamic behaviour and pulmonary deposition of amphotericin B particles were measured using a direct isotopic method based on stable labelling of the drug with 99mTc. Each nebulizer was bench tested for inhaled mass and particle size distribution. Three patients suffering from pulmonary aspergilloma were enrolled for a 4 week clinical study. They received 5 mg of amphotericin B daily delivered by either Fisoneb or DP100 (ultrasonic) or Respirgard II (jet) nebulizers. Deposition of radiolabelled amphotericin B was measured once with each nebulizer using a gamma-camera. In two patients, amphotericin B serum concentration was monitored over a 330 min period after the nebulization had been completed. Inhaled masses of the three nebulizers, assessed as % of labelled drug caught in inspiratory filter in duplicate experiments, were: 5.8 and 3.6% for Respirgard II; 26.5 and 28.3% with Fisoneb; 5.9 and 6.3% for DP100. Mass median aerodynamic diameter (mean +/- SD) results were: 0.28 +/- 0.04 micron with Respirgard II; 4.82 +/- 0.78 microns with Fisoneb; and 2.27 +/- 1.14 microns with DP100. Because of larger particles and significantly greater inhaled mass, Fisoneb delivered more amphotericin B to the central airways, the lung periphery and in the mycetoma lung regions. Amphotericin B serum concentrations correlated with pulmonary deposition and remained below 25 ng.mL-1. No untoward effects were reported by the patients during the 4 week trial.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- P Diot
- Service de Pneumologie, Unité d'Evaluation Clinique, CHU Bretonneau, Tours, France
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Sow O, Diallo AB, Haba F, Diot P, Boissinot E, Lemarie E. Acute respiratory infections in children: a community-based study comparing a primary health center and a pediatric unit, Republic of Guinea. Tuber Lung Dis 1995; 76:4-10. [PMID: 7718846 DOI: 10.1016/0962-8479(95)90571-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
OBJECTIVE A community-based study was carried out in the Republic of Guinea in order to evaluate the frequency of occurrence, severity of illness, risk factors and the results of planned treatment of acute respiratory infections (ARI) in children under the age of 15 years. DESIGN The study was performed over a 1-year period in 2 distinct areas, 1 rural and 1 urban. A total of 2622 ARI were identified among children under 15 years of age. In the rural area, data were collected by primary health-care workers and by 2 physicians who were trained to supervise the study. RESULTS Among the rural population, 1422 ARI were identified. In the city center, Conakry, 1200 ARI were identified in one children's hospital. The child population under 5 years of age was significantly greater in the rural area (95.2%) than in the city center (83.2%) (P < 0.0001). Malnutrition affected 10.6% of all the children. There were discrepancies in symptoms and signs affecting the 2 groups but the severity scores, including children under 5 years of age, were not significantly different: including children under 5 years of age, were not significantly different: 10-11% of the children were considered to have severe disease and 6.2% required urgent referral to hospital. Upper and lower respiratory infections (URI and LRI) were equally represented (49.9% and 50.1% respectively). Distribution of each type of ARI was significantly different in the 2 groups: there were significantly more URI in the city center, especially tonsillitis. Bronchitis and bronchopneumonia occurred significantly more often in the rural area. Pneumonia and bronchopneumonia represented 9.8% of all ARI. Use of antibiotic therapy was known in 2557 patients: 1268 URI and 1289 LRI. In children with URI, 69.7% did not receive antibiotic therapy, 29.9% received 1 antibiotic and 0.03% received 2 antibiotics successively. Children from the city center received significantly more antibiotics than in the rural health center. In children with LRI, 17.8% did not receive antibiotic therapy, 81.7% received 1 antibiotic and 0.05% received 2 antibiotics successively. There was no significant difference between the 2 centers in antibiotic prescription. Clinical outcome showed that 93% of children were considered to be cured at day 7 and 99.4% at day 14. 14 children with severe pneumonia died. The infection cost (antibiotics plus other drugs prescribed as supportive care) was 0.45 US$ per child in the rural area and 9.7 US$ in the children's hospital. CONCLUSION This supervised study constitutes the first large longitudinal study concerning respiratory infections in West Africa. It demonstrates that simple guidelines are valid in order to prevent mortality and complications. Care appropriate to population requirements in term of infectious diseases can be delivered with low cost and low technology.
Collapse
Affiliation(s)
- O Sow
- Centre Hospitalier Universitaire de Conakry, République de Guinée
| | | | | | | | | | | |
Collapse
|
37
|
Diot P, Lemarie E. Wet nebulizers vs metered dose inhalers. Chest 1994; 106:980. [PMID: 8082401 DOI: 10.1378/chest.106.3.980a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
|
38
|
Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lemarie E. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 1994. [PMID: 8004580 DOI: 10.1002/1097-0142(19940701)74] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
BACKGROUND A positive influence of anticoagulant treatment in small cell lung cancer (SCLC) has been suggested by experimental and clinical data. METHODS In a multicenter clinical trial, 277 patients with SCLC were randomized either to receive or not to receive subcutaneous heparin injections for 5 weeks at effective doses, which were monitored by blood coagulation tests. All patients received one of the two chemotherapy regimens studied in this trial, for eight courses in the case of patients with complete or partial response, and subsequently were randomized to receive delayed thoracic radiotherapy after these eight courses. RESULTS In comparison to the 139 patients who did not receive heparin, the 138 patients who received anticoagulant treatment obtained better complete response rates (37% vs. 23%, P = 0.004), better median survival (317 days vs. 261 days, P = 0.01), and better survival rates at 1, 2, and 3 years (40% vs. 30%, 11% vs. 9% and 9% vs. 6%, respectively). At subgroups analysis, the results on survival were obtained for limited forms (P = 0.03) but not for extensive diseases (P = 0.31). No important bleeding or thrombocytopenia was related to heparin treatment. CONCLUSIONS These results confirm the value of anticoagulant treatment in SCLC, already suspected for warfarin and now proven for heparin, but the modes of administration and the biologic explanations for this activity still warrant further investigation.
Collapse
Affiliation(s)
- B Lebeau
- Service de Pneumologie, Hôpital St Antoine, Faculté de Médecine Saint-Antoine, Université Paris VI, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lemarie E. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 1994; 74:38-45. [PMID: 8004580 DOI: 10.1002/1097-0142(19940701)74:1<38::aid-cncr2820740108>3.0.co;2-e] [Citation(s) in RCA: 204] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
BACKGROUND A positive influence of anticoagulant treatment in small cell lung cancer (SCLC) has been suggested by experimental and clinical data. METHODS In a multicenter clinical trial, 277 patients with SCLC were randomized either to receive or not to receive subcutaneous heparin injections for 5 weeks at effective doses, which were monitored by blood coagulation tests. All patients received one of the two chemotherapy regimens studied in this trial, for eight courses in the case of patients with complete or partial response, and subsequently were randomized to receive delayed thoracic radiotherapy after these eight courses. RESULTS In comparison to the 139 patients who did not receive heparin, the 138 patients who received anticoagulant treatment obtained better complete response rates (37% vs. 23%, P = 0.004), better median survival (317 days vs. 261 days, P = 0.01), and better survival rates at 1, 2, and 3 years (40% vs. 30%, 11% vs. 9% and 9% vs. 6%, respectively). At subgroups analysis, the results on survival were obtained for limited forms (P = 0.03) but not for extensive diseases (P = 0.31). No important bleeding or thrombocytopenia was related to heparin treatment. CONCLUSIONS These results confirm the value of anticoagulant treatment in SCLC, already suspected for warfarin and now proven for heparin, but the modes of administration and the biologic explanations for this activity still warrant further investigation.
Collapse
Affiliation(s)
- B Lebeau
- Service de Pneumologie, Hôpital St Antoine, Faculté de Médecine Saint-Antoine, Université Paris VI, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Diot P, Diot E, Lemarie E, Guilmot JL, Baulieu JL, Asquier E, Valat C, Delarue A, Le Pape A. Imaging of pulmonary disease in scleroderma with J001X scintigraphy. Thorax 1994; 49:504-8. [PMID: 8016775 PMCID: PMC474875 DOI: 10.1136/thx.49.5.504] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
BACKGROUND J001X is an acylated poly-galactoside isolated from the membrane of Klebsiella and able to interact with macrophages, mainly in their activated state. The aim of the present study was to determine the ability of 99m-labelled technetium (99mTc)-J001X scintigraphy to image pulmonary disease, defined by high resolution computed tomographic scanning and pulmonary function tests, in patients suffering from scleroderma. METHODS Patients were considered to have pulmonary disease when they had at least two positive signs on high resolution computed tomography, or a decrease in lung volume and single breath carbon monoxide transfer, or both, with no disease process other than scleroderma in their medical history. Positive J001X scintigraphic imaging was defined by symmetrical bilateral pulmonary fixation three and five hours after inhalation of 99mTc-J001X. J001X scintigraphic results were compared with disease activity as indicated by bronchoalveolar lavage (BAL) fluid lymphocytosis. RESULTS Seventeen patients were studied, in 12 of whom J001X scintigraphy was positive. There was no correlation between BAL lymphocytosis and J001X scintigraphic findings, nor between BAL and pulmonary scleroderma. This was not surprising because of the high specificity of macrophage targeting by J001X. CONCLUSIONS Follow up of a larger population over a longer period is needed to establish whether there is a prognostic value for positive J001X scintigraphic findings in scleroderma.
Collapse
Affiliation(s)
- P Diot
- Département des Maladies Respiratories, CHU Bretonneau, Tours, France
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Moumouni H, Garaud P, Diot P, Lemarie E, Anthonioz P. Quantification of cell loss during bronchoalveolar lavage fluid processing. Effects of fixation and staining methods. Am J Respir Crit Care Med 1994; 149:636-40. [PMID: 7509703 DOI: 10.1164/ajrccm.149.3.7509703] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Discrepancies have been reported in differential cell counts according to the diverse processing methods used in bronchoalveolar lavage (BAL) fluid management. The differences have proved to be mainly the result of selective lymphocyte loss, while the exact mechanisms of the phenomenon remain controversial. Observing a similar variation in differentials from differently stained identical smears, we quantified the cell loss due to staining procedures from 45 consecutive satisfactory BAL procedures. To do this, we compared relative lymphocyte recovery on neat pooled lavage in a hemocytometer with that from smears and cytopreps fixed and stained in different ways. We found (1) A significant lymphocyte loss (p < 0.05) whatever the staining method. (2) Different methods of fixation and staining lead to considerable variation in differentials from slides otherwise identically managed. The loss is higher during air-drying fixation followed by staining with an aqueous medium such as Diff-Quik than on spray-fixed slides stained in an alcohol medium such as Papanicolaou stain. (3) The effect of lymphocyte loss on differentials is more important when the initial lymphocytosis is less than 35%, and decreases to nonsignificance when it exceeds 70%. The role of cytocentrifugation or other manipulations in cell loss probably has been overestimated because unknown effects of staining methods were also attributed to these manipulations. We suggest that lymphocyte loss could arise from poor adherence on slides, which is exacerbated during aqueous staining if no artifice (e.g., spray fixation), is used to hold them. Thus, the definition of the long-awaited standard procedure for an accurate differential count of BAL fluid must take into account fixation and staining methods.
Collapse
Affiliation(s)
- H Moumouni
- Départment des Maladies Respiratoires, Centre Hospitalier Universitaire de Tours, France
| | | | | | | | | |
Collapse
|
42
|
Depierre A, Chastang C, Quoix E, Lebeau B, Blanchon F, Paillot N, Lemarie E, Milleron B, Moro D, Clavier J. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994; 5:37-42. [PMID: 8172790 DOI: 10.1093/oxfordjournals.annonc.a058687] [Citation(s) in RCA: 162] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
PURPOSE The purpose of the study was to assess the possible benefit of the combination vinorelbine (NVB)-cisplatin (DDP) in comparison with NVB alone in advanced non-small cell lung cancer (NSCLC), not treated previously. It also involved confirmation of the efficacy of vinorelbine as monotherapy. PATIENTS AND METHODS In this phase III trial, 231 eligible patients were stratified by centre and randomized to receive either NVB alone, 30 mg/m2/week or the combination of NVB 30 mg/m2/week and DDP 80 mg/m2/3 weeks. Patients were to be treated for a minimum of 6 weeks, with the first response assessment performed 9 weeks after the beginning of treatment. RESULTS The two groups differed in terms of objective response rates (16% and 43%, respectively, p = 0.0001) and median time to progression (10 weeks and 20 weeks, p = 0.0001). However, the difference was not significant for median survival time (32 weeks, 33 weeks, p = 0.48). The addition of DDP resulted in an increase in toxicity, in particular renal, hematologic, neurologic and emetic. This toxicity led to treatment discontinuation in 8% and 21% of patients, respectively. Respectively 3% and 13% of patients stopped treatment early during objective response (toxicity or refusal). CONCLUSIONS The NVB-DDP combination increased objective response rates and time to progression in comparison with NVB alone, but did not influence the survival of patients. The activity of NVB in the treatment of advanced NSCLC was confirmed.
Collapse
Affiliation(s)
- A Depierre
- Department of Biostatistics and Medical Informatics, St. Louis Hospital, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Abstract
We report a case of a possible interaction between itraconazole, phenobarbital and carbamazepine. The first plasma itraconazole concentration, measured when the patient had been taking phenobarbital for 2 months, was very low. The second measurement, 2 months after withdrawing phenobarbital, was higher but below the therapeutic range. However, carbamazepine, a well known enzyme inducer, had been initiated 15 days before. 20 days after carbamazepine was withdrawn, the itraconazole concentration 4 hours after administration was near the lower end of the therapeutic range. The mechanism of this possible interaction is probably the same for phenobarbital and carbamazepine, involving hepatic microsomal enzyme system induction.
Collapse
Affiliation(s)
- M Bonay
- Service de Pneumologie, CHU Bretonneau, Tours, France
| | | | | | | | | | | |
Collapse
|
44
|
Diot P, Le Pape A, Becquemin MH, Besnier JM, Boissinot E, Bastides F, Benjemaa M, Choutet P, Lemarie E. Direct isotopic assessment of aerosolized pentamidine deposition: influence of nebuliser. Eur J Med 1993; 2:484-8. [PMID: 8258049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
OBJECTIVES The aim of the present study was to compare the efficiency of pulmonary deposition of pentamidine using the Respirgard II jet nebuliser or the Fison ultrasonic nebuliser with 99m technetium (99m Tc) labelled pentamidine in the current conditions of recommended treatment. The study was designed in three stages, to verify particle size distribution, to validate the isotope labelling, and to compare pulmonary deposition of pentamidine isethionate with the two nebulisers. METHODS Count median aerodynamic diameter and mass median aerodynamic diameter were measured using the velocimetry technique and aerosol dispersion was calculated according to the standard deviation defined by the ratio of diameters between 84.3% and 50% of the total distribution. Stability of labelling was checked both in vitro, by radiochromatography, and in vivo, by the absence of free technetium thyroid fixation after intravenous injection of the preparation to a rat and inhalation by baboons. The direct isotopic technique was used to compare pulmonary deposition of 300 mg aerosolized 99m Tc labelled pentamidine isothionate with the two nebulisers in four HIV patients treated with primary prophylaxis. RESULTS Count median aerodynamic diameter and mass median aerodynamic diameter (MMAD) were higher with Fisoneb than with Respirgard II. Nevertheless Fisoneb MMAD remained in the optimal range for peripheral deposition. In one patient, pentamidine lung burden was higher using the Respirgard II (13% of dose originally in nebuliser) when compared with the Fisoneb (10.2% of dose originally in nebuliser). A better result was obtained in the 3 other patients with Fisoneb (mean = 14.3%) compared with Respirgard II (mean = 3.8%). In all 4 patients gastric contamination was higher with Fisoneb (mean = 5.2%) as compared with Respirgard II (mean = 2.6%). Cough and bronchospasm were not observed with either device. CONCLUSION This study showed that Fisoneb, a practical and cheap nebuliser which has proved to be effective in clinical studies when used for pentamidine nebulisation, leads to correct particle size distribution and pulmonary deposition of the drug. We believe that such studies to evaluate aerosol characteristics should be recommended for any kind of nebuliser.
Collapse
Affiliation(s)
- P Diot
- Département des Maladies Respiratoires, CHU Bretonneau, Tours, France
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Dautzenberg B, Scheimberg A, Brambilla C, Camus P, Godard P, Guerin JC, Lemarie E, Rezvani Y, Rosembaum M, Tuchais E. Comparison of two oral antibiotics, roxithromycin and amoxicillin plus clavulanic acid, in lower respiratory tract infections. Diagn Microbiol Infect Dis 1992; 15:85S-89S. [PMID: 1617930 DOI: 10.1016/0732-8893(92)90133-e] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
In a randomized, multicenter, open-label study, 490 ambulatory adult patients with lower respiratory tract infection (LRTI) were randomized to roxithromycin (ROX) 150 mg b.i.d. orally (n = 244) or amoxicillin plus clavulanic acid (AMX + CA) as 500 mg AMX + 125 mg CA t.i.d orally (n = 24). Clinical results were analyzed in 477 patients with acute bronchitis (79%), chronic bronchitis (CB) (14%), and pneumonia (7%). There were significantly more patients with underlying disease (cardiovascular diseases, p = 0.045; and alcoholism, (p less than 0.001), and more patients over the age of 65 years (p = 0.045) in the ROX group. Overall clinical efficacy was similar in both groups: 88% (206:235) in the ROX group and 85% (205:242) in the AMX + CA group. Side effects were reported in 67 cases (28%) in the AMX + CA group and in 21 cases (9%) in the ROX group (p less than 0.0001), causing withdrawal in 21 and three cases, respectively (p less than 0.001). Thus, despite being administered to a significantly older and more ill group of patients with LRTI, roxithromycin was as effective as amoxicillin plus clavulanic acid and better tolerated.
Collapse
Affiliation(s)
- B Dautzenberg
- Thoracic Department Pitié Salpêtrière Hospital, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC. A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 1991; 14:115-9. [PMID: 1851385 DOI: 10.1097/00000421-199104000-00004] [Citation(s) in RCA: 188] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Navelbine (vinorelbine, NVB) is the first semisynthetic 5'-nor-vinca-alkaloid selected for clinical trial. NVB has been shown to have a good level of activity against different experimental solid tumors in animals, with low neurotoxicity. In the phase II study, 78 patients with an inoperable non-small-cell lung cancer (NSCLC) were treated with NVB at a weekly dose of 30 mg/m2. No patient had previously received chemotherapy. Twenty-three of the 78 eligible patients showed a partial response (29.4% with a 95% confidence limits: 19.5-39.5). Eight patients were not evaluable and the percentage of partial response were 32.8% in the evaluable patients group. The median response duration was 34 weeks, and the median survival time for the overall population reached 33 weeks. Grade 3-4 leukopenia was seen in 12.5% of cycles. No thrombocytopenia occurred. At the dosage schedule used, NVB seems a very promising agent in the treatment of NSCLC.
Collapse
Affiliation(s)
- A Depierre
- Service de Pneumologie, CHR de Besançon, France
| | | | | | | | | | | |
Collapse
|
47
|
Diot P, Jonville AP, Gerard F, Bonnelle M, Autret E, Breteau M, Lemarie E, Lavandier M. [Possible interaction between theophylline and fluvoxamine]. Therapie 1991; 46:170-1. [PMID: 1905066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
48
|
Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC. Efficacy of Navelbine (NVB) in non-small cell lung cancer (NSCLC). Semin Oncol 1989; 16:26-9. [PMID: 2540532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- A Depierre
- CHR/Hôpital Saint-Jacques, Besancon, France
| | | | | | | | | | | |
Collapse
|
49
|
Douay L, Gorin NC, Mary JY, Lemarie E, Lopez M, Najman A, Stachowiak J, Giarratana MC, Baillou C, Salmon C. Recovery of CFU-GM from cryopreserved marrow and in vivo evaluation after autologous bone marrow transplantation are predictive of engraftment. Exp Hematol 1986; 14:358-65. [PMID: 3519263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
In 18 patients with non-Hodgkin's lymphomas or solid tumors treated with intensive chemotherapy and/or total-body irradiation followed by autologous bone marrow transplantation (ABMT), we assessed the value of granulocyte-macrophage progenitor cells (CFU-GM) monitoring to predict engraftment. We studied CFU-GM in cryopreserved marrow and attempted to settle whether detection of CFU-GM in vivo after ABMT has a predictive value on engraftment. Our data showed: The absence of linear correlation linking recovery of hematopoiesis to the dose of CFU-GM/kg infused. The existence of a CFU-GM threshold in respect to engraftment. Patients receiving doses of CFU-GM greater than 10(3)/kg had significantly faster recovery kinetics for hematopoiesis than did patients receiving doses below this threshold, with median recoveries to 0.5 and 1.0 X 10(9) neutrophils/liter, respectively, on days 14 and 15 versus days 29 and 31.5 (p less than 0.05 and p less than 0.02) and median recoveries to 1.0 and 2.5 X 10(9) leukocytes/liter respectively, on days 12.5 and 16 versus days 28 and 30.5 (p less than 0.05 and p less than 0.02). Considering the entire course of events during the first four weeks, we were able to show that white blood cell recovery was significantly faster in the group of patients receiving doses of CFU-GM greater than 10(3)/kg (p less than 0.001). Sequential studies of the reappearance of CFU-GM in marrow and peripheral blood indicated that the kinetics of CFU-GM recovery in vivo after ABMT predict engraftment. By day 7 after the graft, CFU-GM were already detectable in the marrow at a level of 10% of the dose infused for patients with optimal engraftment--median time to recovery to 1.0 and 2.5 X 10(9) leukocytes/liter and 1.0 X 10(9) neutrophils/liter on days 11, 15, and 14.5 versus days 18, 23, and 23 (p less than 0.02, less than 0.05, and less than 0.05), respectively after. On day 10 after ABMT, a 15% CFU-GM level in bone marrow confirmed engraftment, with a significant correlation of all parameters studied--1.0 and 2.5 X 10(9) leukocytes/liter (p less than 0.02 and less than 0.01), 0.5 and 1.0 X 10(9) neutrophils/liter (p less than 0.05), 50.0 and 100.0 X 10(9) platelets/liter (p less than 0.05). On day 14, a 50% CFU-GM level was reached in all patients with optimal engraftment; p less than 0.01 on 1.0, and 2.5 X 10(9) leukocytes on 0.5 and 1.0 X 10(9) neutrophils/liter. The detection of circulating CFU-GM in the blood by day 10 or 14 indicated engraftment.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
|
50
|
Lemarie E, Musset M, Charbonnier C, Renoux M, Renoux G. Clinical characterization of imuthiol. Methods Find Exp Clin Pharmacol 1986; 8:51-4. [PMID: 3010015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Imuthiol is a nontoxic agent recruting and regulating T cells. Phase III studies in chronic bronchitis and bronchiectasis showed that immune functions were restored to normal, or near normal values. Cure was obtained in rheumatoid arthritis, tuberculosis and chronic infections in the elderly. Imuthiol is an effective agent for the treatment of syndromes and disease states where the underlying defect is a T-cell deficiency or dysfunction.
Collapse
|